Biofrontera AG et al. v. Sun Pharmaceutical Industries, Inc.

IPR2024-00874

Biofrontera AG et al. challenged U.S. Patent No. 11,697,028 held by DUSA Pharmaceuticals, Inc., alleging obviousness under 35 U.S.C. § 103. The challenge focuses on the combination of prior art references to demonstrate that specific Photodynamic Therapy (PDT) illuminator claims are unpatentable.

Jurisdiction
US PTAB
Case Number
IPR2024-00874
Decision Date
30 April 2024
Filing Date
30 April 2024

Detailed Summary

This Petition challenges U.S. Patent No. 11,697,028 by Biofrontera AG et al., asserting obviousness over combinations of prior art references under § 103. The Petitioner presents three specific grounds: Ground 1 combines Larsen, Bansal, and Jones against Claims 1, 2, 4-8, 16-21; Ground 2 uses Larsen, Bansal, Jones, and Anderson to show obviousness for optimized PDT conditions (Claims 2-4); and Ground 3 adds Mackinnon's sensor technology to the existing combination for improved targeting (Claims 10, 11, 13, 14).

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Biofrontera AG et al. vs Sun Pharmaceutical Industries, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call